Organigram Global Inc.

NASDAQ:OGI

Drug Manufacturers - Specialty & Generic

Healthcare
$0.68 -1.74%

-$0.02 today

Market cap
$95.40M
Beta
1.84
P/E (TTM)
-7.2
EPS (TTM)
-$0.19
52W Low $0.97High $2.24

Volume 0.62M

Average 0.67M

OGI EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Organigram Global Inc.NASDAQ: OGI

EBITDA · Q2 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q2 FY2026 EBITDA was -CA$4.76M, compared with -CA$2.74M a year earlier. Trailing-twelve-month EBITDA was CA$5.64M.

Context

  • EBITDA amounted to 7.9% of revenue in FY2025, down 6.8 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of CA$102.07M (+791.6%) for the fiscal year ending Sep 2026, a step up from the +37.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$4.76M-404.7% QoQ
Last fiscal yearSep 2025
-CA$14.76M+37.4% YoY
LTMMar 2026
CA$5.64M-19.8% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-73.5%+261.7%+335.2 pp
1 year+37.4%+791.6%+754.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

CAD · from the income statement

Latest · FY2025
(14.76M) CAD
Year-over-year change
+37.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How OGI compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -19.8% is the 6th highest of 9, against a peer median of +9.8%.
  • EBITDA amounts to 2.1% of revenue for OGI, versus a peer median of 20.6%.
OGI Competitors
EBITDA for OGI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INFUInfuSystem Holdings, Inc.LTM Mar 2026$25.86M USD+21.2%+19.2%18.2%
ELMDElectromed, Inc.LTM Mar 2026$14.78M USD+39.5%+46.7%20.6%
ACBAurora Cannabis Inc.LTM Mar 2026CA$10.48M CAD-79.6%—3.4%
OGIOrganigram Global Inc.LTM Mar 2026CA$5.64M CAD-19.8%—2.1%
LFCRLifecore Biomedical, Inc.LTM Mar 2026-$1.03M USD——0.8%
DERMJourney Medical CorporationLTM Mar 2026-$1.44M USD-0.6%—2.2%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-$52.72M USD+20.1%—161.1%
IVAInventiva S.A.FY2025-€128.15M EUR+23.0%—2858.6%
HSDTSolana CompanyLTM Mar 2026-$135.55M USD-1012.4%—1413.6%
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$158.55M USD-341.7%—8932.3%
Peer median (excluding OGI) —+9.8%+33.0%20.6%

Competitors are the stored peer set for OGI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue79.16M145.81M149.21M159.84M186.09M
Cost of Revenue107.56M114.24M114.13M112.32M179.26M
Gross Profit(28.4M)31.57M35.07M47.52M6.83M
Gross Margin-35.9%21.7%23.5%29.7%3.7%
Research & Development3.45M5.96M12.19M11.2M10.95M
Selling, General & Admin46.47M59.21M71.68M68.14M86.88M
Operating Expenses63.42M74.72M271.48M83.2M70.24M
Depreciation & Amortization31.03M24.91M23.43M12.08M12.91M
EBITDA(96.71M)10.97M(25.37M)(23.59M)(14.76M)
EBITDA Margin-122.2%7.5%-17.0%-14.8%-7.9%
Operating Income(91.82M)(43.15M)(242.74M)(35.67M)(63.41M)
Operating Margin-116.0%-29.6%-162.7%-22.3%-34.1%
Interest Income003.69M0825.7K
Interest Expense2.96M429K277.85K00
Other Income / Expenses(38.88M)28.78M(184.21M)(9.77M)35.74M
Income Before Tax(130.7M)(14.37M)(233M)(45.44M)(27.66M)
Pre-Tax Margin-165.1%-9.9%-156.2%-28.4%-14.9%
Income Tax Expense0(88K)(3.52M)0(9.89M)
Net Income(130.7M)(14.28M)(229.48M)(45.44M)(17.78M)
Net Margin-165.1%-9.8%-153.8%-28.4%-9.6%
EPS (Basic)(2.04)(0.18)(2.82)(0.48)(0.14)
EPS (Diluted)(2.04)(0.18)(2.82)(0.48)(0.14)
Weighted Avg Shares64.03M80.01M81.29M95.29M127.67M
Weighted Avg Shares (Diluted)64.03M85.3M81.29M95.29M127.67M

Organigram Global Inc.

NASDAQ:OGI

Intrinsic Alpha fair value

Locked

Current Price

$0.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.